fashion -WSS

fashion

author：hotspot 2025-09-05 13:41:08 - browse：8353

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： FDA approves first treatment for ultra

WSS

Orangutan used medicinal plant to treat wound, first time ever seen

Evacuations in place as 3 wildfires burn in eastern Washington state

Melinda French Gates resigns from Gates Foundation

Diversity in clinical trials starts with building trust, experts say

Cholera vaccine supply gets boost as demand surges globally

MassMutual is introducing free genetic testing for members

knowledge

fashion

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The pain doctors face in trying to build their families

In Memoriam: Notable people who died in 2023

Close Medicare's dangerous gaps in addiction treatment coverage

How one medical school became remarkably diverse

MassMutual is introducing free genetic testing for members

Cancer drug shortages should be causing more outrage

Living with Hashimoto's and celiac disease, and med school, too

Moonlake's readout produced a cash windfall. Risks remain

Beware the threat of staffing cuts at the CDC

explore

MassMutual is introducing free genetic testing for members

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

MassMutual is introducing free genetic testing for members

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

MassMutual is introducing free genetic testing for members

Health care needs a new profession: neuroimaging counseling

hotspot

knowledge

explore

hotspot